Eton Pharmaceuticals (NASDAQ:ETON) Earns Buy Rating from HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $11.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 18.03% from the company’s current price. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q1 2025 earnings at $0.09 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum increased their price target on Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Price Performance

ETON stock traded down $1.14 during mid-day trading on Wednesday, reaching $9.32. 103,087 shares of the company’s stock were exchanged, compared to its average volume of 93,002. The company has a market cap of $240.83 million, a price-to-earnings ratio of -44.27 and a beta of 1.25. The stock’s 50 day moving average is $7.29 and its 200 day moving average is $4.93. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $11.11.

Insider Activity

In other news, major shareholder Opaleye Management Inc. bought 11,248 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were acquired at an average price of $7.22 per share, for a total transaction of $81,210.56. Following the completion of the transaction, the insider now directly owns 2,730,000 shares in the company, valued at $19,710,600. The trade was a 0.41 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have bought a total of 85,600 shares of company stock worth $462,674 over the last quarter. 14.89% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eton Pharmaceuticals in the third quarter valued at approximately $54,000. Westside Investment Management Inc. increased its holdings in shares of Eton Pharmaceuticals by 2.0% in the second quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock valued at $1,926,000 after purchasing an additional 11,440 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock valued at $585,000 after purchasing an additional 18,898 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares during the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.